Neurocrine Biosciences, Inc. (NBIX) Stock: Price, Forecast & Analyst Target
Neurocrine Biosciences, Inc. (NBIX) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $162.86 (-1.84%), as of the Nov 18, 2026 trading session; market cap $16.5B.
Educational signal · not a buy or sell recommendation · How to read this
Neurocrine Biosciences, Inc. · NBIX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Neurocrine Biosciences is a profitable commercial-stage biotechnology company whose primary asset, INGREZZA, treats tardive dyskinesia, while partnered medicines and an internally developed pipeline broaden its reach across neurological, endocrine and psychiatric disorders. The case depends on whether INGREZZA-led product growth can continue funding heavier research and commercial investment without allowing earnings and cash conversion to lag behind sales.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Neurocrine Biosciences (NBIX)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $795M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 6 of the last 8 reports
- Altman Z 7.34 · Piotroski F 5
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $162.86 | |
| Change on the day | -1.84% | |
| 52-week range | $122.14–$186.12 | |
| Market capitalisation | $16.5B | — |
| Price / earnings (trailing) | 23.80 | |
| Shares traded on the day | 1.60M | |
| Beta (volatility vs the S&P 500) | 0.33 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Neurocrine Biosciences (NBIX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 18, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Neurocrine Biosciences (NBIX), and what does it report?
Short answer · as of
Neurocrine develops and commercializes medicines rather than relying solely on clinical milestones or licensing payments.
Research dated 2026-09-13.
INGREZZA is the main commercial asset, while ONGENTYS, ORILISSA and ORIAHNN extend the marketed portfolio and several experimental programs address epilepsy, depression, schizophrenia and related conditions through internal work and collaborations.
Reported revenue is overwhelmingly product revenue, with collaboration revenue contributing only a small remainder. The income statement therefore measures a functioning drug franchise alongside the cost of expanding the pipeline, not merely the progress of a precommercial biotechnology company.
What do the latest results show for Neurocrine Biosciences (NBIX)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $795M.
Research dated 2026-09-13.
Recent revenue reached the highest level in the reported quarterly series and exceeded the prevailing estimate. Operating and net profit nevertheless declined from the preceding period, while diluted earnings fell short of expectations.
The financial statements show the immediate mechanism: research and development spending rose, and selling, general and administrative expense increased even more sharply. Management separately said its expense outlook now incorporates transaction and integration costs plus purchase-accounting effects, while also raising its patient-reach outlook for tardive dyskinesia and chorea associated with Huntington’s disease.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $795M | $210M | $2.04 (diluted) |
| Q4 FY2025 | $806M | $154M | $1.48 (diluted) |
| Q1 FY2026 | $815M | $198M | $1.91 (diluted) |
| Q2 FY2026 | $959M | $144M | $1.39 (diluted) |
What are the financial strengths and risks for Neurocrine Biosciences (NBIX)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Neurocrine remains profitable and generates positive operating cash flow, with high gross margins, modest leverage relative to equity and strong distress-screen results. Capital expenditure is light beside operating cash generation, giving the commercial franchise meaningful capacity to support development spending.
The balance-sheet picture requires more care than the earnings line. Cash and short-term investments fell sharply across the reported window and ended near total debt, although additional long-term investments lift the broader cash-and-investment total above debt. Rising research and commercial costs could pressure margins further if product growth cools, while the recent cash movement makes acquisition, integration and other non-operating uses of funds important to track separately from operating performance.
What should you watch next at Neurocrine Biosciences (NBIX)?
Short answer · as of
Current published price targets run low $165.00 · high $225.00 · consensus $203.41 · median $210.00 against a quoted price of $162.86 (as of Nov 18, 2026).
Research dated 2026-09-13.
INGREZZA-led product revenue should be read alongside patient reach in tardive dyskinesia and Huntington’s disease chorea, because management tied its raised outlook to serving more patients in those indications. The scheduled earnings release also offers a direct test of whether revenue momentum is translating into operating profit after the recent jump in research and commercial expense.
Cash and investment movements deserve a separate check. The useful questions are whether operating cash generation remains positive, how transaction and integration costs develop, and whether the sharp reduction in short-term liquidity reflects continuing deployment or a stabilized balance-sheet position. Longer-range estimates assume continued expansion, but their wide revenue range makes execution more informative than the average forecast alone.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Oct 28, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Neurocrine Biosciences compare with its peers?
Short answer
Neurocrine Biosciences's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Neurocrine differs from development-heavy biotechnology businesses because marketed medicines already produce substantial revenue, profit and operating cash flow. It also differs from broadly diversified pharmaceutical groups: product revenue is concentrated around a primary commercial asset even as the company funds a wide neurological and psychiatric pipeline and uses licensing partnerships to extend its portfolio.
That combination gives Neurocrine an established commercial engine and unusually high gross profitability, but it also links near-term financial performance closely to INGREZZA demand and the spending required to build future growth beyond that franchise.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| Neurocrine Biosciences (NBIX) — this page | $162.86 | $16.5B | 95 |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| $50.97 Nov 18, 2026 | $31.4B | 72 5-pillar Nov 18, 2026 | |
| $60.75 Nov 18, 2026 | $11.6B | 40 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $165.00 – $225.00
- Consensus target
- $203.41
- Median target
- $210.00
Consensus record · Captured .
Measured against a quoted price of $162.86 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 4, 2026
- Transactions
- 122
- Identified insiders
- 20
- Purchases
- 0
- Sales
- 39
- Other transactions
- 83
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NBIX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.13% | $29.27M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is INGREZZA so important to Neurocrine Biosciences?
INGREZZA is Neurocrine’s primary commercial asset, and product sales account for nearly all reported revenue. Its demand therefore supports current earnings and helps finance the broader clinical pipeline.
Why did Neurocrine’s profit fall while revenue rose?
Research spending increased and selling, general and administrative expense climbed sharply, more than offsetting the benefit of higher revenue. Management also incorporated transaction, integration and purchase-accounting effects into its expense outlook.
Does Neurocrine’s cash decline signal an operating burn problem?
The company continued producing positive operating cash flow, so the decline is not explained by operating burn alone. Recent acquisition activity and management’s transaction-cost guidance provide relevant context, while the broader investment balance makes the short-term cash figure an incomplete view of available financial resources.
What should investors watch in Neurocrine’s INGREZZA outlook?
Management linked its raised outlook to reaching more people with tardive dyskinesia or chorea associated with Huntington’s disease. Product revenue, patient reach and the expense required to support that growth should be evaluated together.
What is the NBIX stock price today?
The last price recorded for Neurocrine Biosciences, Inc. (NBIX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NBIX price target?
The analyst consensus price target for Neurocrine Biosciences, Inc. (NBIX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com